Cargando…
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining f...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056330/ https://www.ncbi.nlm.nih.gov/pubmed/27777881 http://dx.doi.org/10.5306/wjco.v7.i5.387 |
_version_ | 1782458876135735296 |
---|---|
author | Castaneda, Carlos A Mittendorf, Elizabeth Casavilca, Sandro Wu, Yun Castillo, Miluska Arboleda, Patricia Nunez, Teresa Guerra, Henry Barrionuevo, Carlos Dolores-Cerna, Ketty Belmar-Lopez, Carolina Abugattas, Julio Calderon, Gabriela De La Cruz, Miguel Cotrina, Manuel Dunstan, Jorge Gomez, Henry L Vidaurre, Tatiana |
author_facet | Castaneda, Carlos A Mittendorf, Elizabeth Casavilca, Sandro Wu, Yun Castillo, Miluska Arboleda, Patricia Nunez, Teresa Guerra, Henry Barrionuevo, Carlos Dolores-Cerna, Ketty Belmar-Lopez, Carolina Abugattas, Julio Calderon, Gabriela De La Cruz, Miguel Cotrina, Manuel Dunstan, Jorge Gomez, Henry L Vidaurre, Tatiana |
author_sort | Castaneda, Carlos A |
collection | PubMed |
description | AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays (TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS: Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response (pCR) (P = 0.0251) and outcome (P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections (ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. Post-NAC lesions with pCR had similar TIL levels than those without pCR (P = 0.6331). NAC produced a TIL decrease in full-face sections (P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival (DFS). Higher counts of CD3 in pre-NAC samples had longer overall-survival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR. CONCLUSION: TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related. |
format | Online Article Text |
id | pubmed-5056330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-50563302016-10-24 Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy Castaneda, Carlos A Mittendorf, Elizabeth Casavilca, Sandro Wu, Yun Castillo, Miluska Arboleda, Patricia Nunez, Teresa Guerra, Henry Barrionuevo, Carlos Dolores-Cerna, Ketty Belmar-Lopez, Carolina Abugattas, Julio Calderon, Gabriela De La Cruz, Miguel Cotrina, Manuel Dunstan, Jorge Gomez, Henry L Vidaurre, Tatiana World J Clin Oncol Basic Study AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays (TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS: Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response (pCR) (P = 0.0251) and outcome (P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections (ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. Post-NAC lesions with pCR had similar TIL levels than those without pCR (P = 0.6331). NAC produced a TIL decrease in full-face sections (P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival (DFS). Higher counts of CD3 in pre-NAC samples had longer overall-survival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR. CONCLUSION: TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related. Baishideng Publishing Group Inc 2016-10-10 2016-10-10 /pmc/articles/PMC5056330/ /pubmed/27777881 http://dx.doi.org/10.5306/wjco.v7.i5.387 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Castaneda, Carlos A Mittendorf, Elizabeth Casavilca, Sandro Wu, Yun Castillo, Miluska Arboleda, Patricia Nunez, Teresa Guerra, Henry Barrionuevo, Carlos Dolores-Cerna, Ketty Belmar-Lopez, Carolina Abugattas, Julio Calderon, Gabriela De La Cruz, Miguel Cotrina, Manuel Dunstan, Jorge Gomez, Henry L Vidaurre, Tatiana Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title_full | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title_fullStr | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title_full_unstemmed | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title_short | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
title_sort | tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056330/ https://www.ncbi.nlm.nih.gov/pubmed/27777881 http://dx.doi.org/10.5306/wjco.v7.i5.387 |
work_keys_str_mv | AT castanedacarlosa tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT mittendorfelizabeth tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT casavilcasandro tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT wuyun tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT castillomiluska tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT arboledapatricia tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT nunezteresa tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT guerrahenry tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT barrionuevocarlos tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT dolorescernaketty tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT belmarlopezcarolina tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT abugattasjulio tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT calderongabriela tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT delacruzmiguel tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT cotrinamanuel tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT dunstanjorge tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT gomezhenryl tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy AT vidaurretatiana tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy |